GlassScriptPhysician profile
Daniel T Rubino
NPI 1669481578
$4,313.39
in general payments reported to CMS, 2019-2025
33 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
See the full distribution for Neuromusculoskeletal Medicine, Sports Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $338 · 2021: $597 · 2022: $863 · 2023: $798 · 2024: $634 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.36 | 2021-2025 | Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,014.92 | 2019-2025 | Relistor |
| Pfizer INC. | $373.66 | 2019-2025 | |
| Lilly USA, LLC | $188.21 | 2019-2024 | Emgality |
| Idorsia Pharmaceuticals US INC | $149.83 | 2022-2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $139.85 | 2019-2025 | Belbuca |
| Amgen INC. | $137.57 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $121.32 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $107.85 | 2023-2024 | Ztlido |
| Lundbeck LLC | $95.50 | 2024-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $94.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $74.81 | 2020-2021 | |
| Almatica Pharma LLC | $72.74 | 2021-2022 | |
| Mdd US Operations, LLC | $70.29 | 2019-2020 | |
| Redhill Biopharma INC. | $69.31 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $54.10 | 2020-2025 | Tirosint, Licart, Flector |
| Eisai INC. | $47.40 | 2020-2021 | |
| Daiichi Sankyo INC. | $46.02 | 2019 | |
| Azurity Pharmaceuticals, INC. | $43.85 | 2023 | Horizant |
| Assertio Therapeutics, INC. | $41.61 | 2019 | |
| Allergan, INC. | $38.14 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $33.90 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.91 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.93 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.41 | 2021-2022 | |
| Orexo US, INC. | $26.08 | 2021-2022 | |
| Valinor Pharma, LLC | $24.32 | 2023 | Movantik |
| Upsher-Smith Laboratories LLC | $21.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.16 | 2021 | |
| Clarus Therapeutics INC. | $16.22 | 2021 | |
| Bausch Health US, LLC | $14.66 | 2019 | |
| Shionogi INC | $12.35 | 2019 | |
| Sentynl Therapeutics, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rubino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.